ARTL ▼ -7.4% - Artelo Biosciences, Inc. $ARTL - Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings Artelo Biosciences shares fell 7.4% despite the company filing a new provisional patent application for ART27.13 targeting obesity, including combinations with GLP-1 receptor agonists, based on unexpected nonclinical findings. The decline suggests investors may have viewed the announcement as insufficient to drive near-term value, or that the "unexpected" nonclinical results warranted caution rather than enthusiasm at this stage of development. 23-SEP-2026 07:33 AM ET